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various therapeutic agents, including drugs and genes. Indeed,
liposomes and nanoparticles equipped with homing devices for
the targeting of receptors over-expressed on the hepatic tissue
have improved the treatment of various liver diseases. In this
review, various nanotechnology approaches employed for the
treatment/imaging of liver disease, either in preclinical or in
clinic are discussed.
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Hepatic ﬁbrosis, microbial infections, and hepatocellular carci-
noma are the major sources of hepatic diseases causing signiﬁ-
cant mortality worldwide; their prevalence is rising despite the
availability of standard medication and/or vaccination. An impor-
tant drawback of standard therapy arises from the inability to
deliver sufﬁcient concentration of therapeutics to the liver dis-
ease and/or contribution to undesirable effects [1,2].
Nanotechnologies constructed with biocompatible materials
possess great potential in delivering drugs in a more speciﬁc
manner: either passively by optimizing the physicochemical
properties of the drug nanocarriers (such as the size and the sur-
face properties) or actively by using organ/tissue-speciﬁc homing
devices which allow the targeting of the disease site, simulta-
neously minimizing side-effects [3]. In this article, we discuss
various nanotechnology-based approaches at preclinical or clini-
cal stage, for improving the efﬁcacy and safety of liver disease
chemotherapy. For clarity, the terms ‘‘nanotechnology’’, ‘‘nanode-
vice’’, or ‘‘nanoformulations’’ are used in this review to deﬁne
supramolecular assemblies of several to several hundred nano-
meters for therapeutic or imaging purposes (also called ‘‘nano-
medicine’’). Nanomedicines are generally assembled using
phospholipids (i.e. liposomes), polymers (i.e. nanoparticles or
micelles), or iron based materials (i.e. ultra small iron oxide
nanoparticles, USPIO).Journal of Hepatology 20
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being chronic alcohol consumption, viral infections like hepatitis
B, C, genetic abnormalities, etc. The chronic liver injury results in
the activation of a variety of cell types of resident liver macro-
phages (Kupffer cells), endothelial cells and platelets, and pro-
motes an inﬂux of leucocytes, which results in the generation
of lipid peroxides, reactive oxygen species (ROS)/free radicals
and nitric oxide, and diverse cytokines. This stimulates the phe-
notypic activation of hepatic stellate (HS) cells which further
transform into myoﬁbroblasts possessing ﬁbrogenic properties
[4]. The activated HS cells induce the release of diverse matrix
metalloproteinases (MMPs) which further causes the degradation
of the normal matrix and its replacement by ﬁbrillar collagen
deposition. The uncontrolled ﬁbrosis may lead to cirrhosis, which
may also end up into hepatocellular carcinoma (HCC).
In the clinical setting, the conventional anti-ﬁbrotic treat-
ments are of little success, often due to non-speciﬁc drug dispo-
sition. Thus, the aim of efﬁcient antiﬁbrotic drug delivery using
nanodevices is to achieve liver-speciﬁcity with subsequent tar-
geting of the ﬁbrotic region. In this context, HS cells have been
the major target for delivering drugs to ﬁbrosis using a lipo-
some/nanoparticle approach. Various receptor types expressed/
over-expressed on HS cells have been targeted using the relevant
targeting ligands conjugated at the surface of liposomes (Fig. 1):
(i) Targeting Mannose 6-phosphate (M6P)/insulin like growth
factor-II receptor: this receptor possessing binding site for M6P,
overexpressed on HS cells, has been targeted using albumin-
M6P (albumin chemically modiﬁed with 28 M6P groups). Albu-
min-M6P selectively binds to phenotypic activated HS cells in
rat and human ﬁbrotic livers in vitro, and also signiﬁcantly accu-
mulates (58% injected dose) in the rat ﬁbrotic liver in vivo after
i.v. injection, by endocytosis [5]. Therefore, liposomes decorated
with the albumin-M6P were designed; following i.v. injection into
the rat ﬁbrotic liver, they were found to efﬁciently deliver the
encapsulated inactivated hemagglutinating virus of Japan (HVJ)
containing a plasmid DNA holding luciferase as reporter gene [6].
(ii) Targeting Integrins: type VI collagen (a matrix protein in-
volved in cell adhesion), widely distributed in HS cells, expresses
integrins. Thus, the RGD (Arginine-Glycine-Aspartate) sequence
has been used as a homing device to target collagen VI and hence
the HS cells in ﬁbrotic liver [7]. For instance, RGD-coupled steri-
cally-stabilized liposomes have efﬁciently delivered the encapsu-
lated interferon (IFN)a-1b to the ﬁbrotic liver in rat, achieving a






Fig. 1. Schematic representation of hepatic stellate cell targeting using a
PEGylated liposome decorated with a hepatocyte-speciﬁc targeting ligand.
Clinical Application of Basic Science(iii) Targeting high-afﬁnity membrane receptor for retinol
binding protein (rRBP): HS cells, speciﬁcally being retinoid stor-
ing cells in the liver, express rRBP receptors that function to bind
and take-up vitamin A. Thus, vitamin A-conjugated liposomes
loaded with siRNA against gp46 (the rat homolog of human heat
shock protein 47), involved in inhibition of collagen secretion,
were injected i.v. into ﬁbrotic liver-bearing rats. Considerable
suppression of collagen secretion and reduction in ﬁbrosis were
observed following this treatment [9].
(iv) Targeting galactosyl receptor: the galactosyl receptor ex-
pressed on the hepatocytes mediates the internalization of
molecular asialoglycoproteins and small particles. With this in
mind, liposomes decorated with p-aminophenyl a-D-galacto-
pyranoside, which binds to galactosyl receptor, have been used
as carriers for targeted i.v. delivery of the antioxidant ﬂavanoid
quercetin. These quercetin-loaded galactosylated liposomes
(GLQ) accumulated 1.7-fold more in the rat liver than non-galac-
tosylated liposomal quercetin (nGLQ) and 3.4-fold more than free
quercetin. The liposomal formulation showed considerable
hepatoprotection from oxidative damage, by preventing the
depletion of native antioxidant levels, and also by inhibiting the
collagen and 4-hydroxyproline deposition responsible for ﬁbro-
genesis [10].
The scavenger receptors expressed on liver endothelial cells
and Kupffer cells have also been targeted using nanoparticles.
For instance, i.v. injected albumin-dexamethasone nanoparticles
(without any speciﬁc targeting moiety) were found to spontane-
ously concentrate into non-parenchymal hepatic cells which are
mediators of inﬂammation. This treatment resulted in an efﬁcient
inhibition of TNF-a production and hence in a signiﬁcant
decrease of ﬁbrosis compared to the free dexamethasone treat-
ment in rats [11].
Even if the biocompatibility of selenium nanoparticles
remains questionable, melatonin loaded onto selenium nanopar-
ticles administered orally resulted in a considerable protection of
the liver from Bacillus Calmette–Guerin/lipopolysaccharide-
induced hepatic injury in mice. The efﬁcacy of this treatment
was attributed to increased levels of superoxide dismutase and
glutathione peroxidase, and to suppression of nitric oxide levels
in plasma and tissues [12]. Similarly, the extracellular superoxide
dismutase (ESD) plasmid intravenously injected as polycationic
liposomal complex to acute liver injury mouse models resulted1462 Journal of Hepatology 2011in signiﬁcant protection of the liver by inducing an increase in
serum superoxide dismutase and hepatic glutathione levels,
simultaneously reducing the lipid peroxidation [13].Hepatic infections
Microbial infections including viral, fungal, bacterial, and parasite
infections constitute the major sources of liver infections.
Depending upon the type of infection, the treatment target could
be either hepatocytes or liver macrophages.
Targeting hepatocytes
Hepatitis B is a life-threatening viral infection in which the virus
replicates in hepatic cells, leading to the expression of viral anti-
gens on the cell surface. The treatment of chronic HBV includes
the administration of PEGylated IFN-a associated with ribavirin.
While PEGylated IFN-a has shown prolonged half-life and
enhanced therapeutic index comparatively to IFN-a [14], it is
often associated with dose-limiting side-effects, such as inﬂu-
enza-like symptoms, neurological symptoms, and thrombocyto-
penia. On the other hand, treatment using oral anti-HBV drugs
such as nucleoside and nucleotide analogs was not satisfactory
in long-term elimination of viral load and has been associated
with resistance. Thus, the delivery of anti-HBV agents through
nanotechnology approaches may be beneﬁcial in potentially
accumulating these agents at the disease site and minimizing
the non-speciﬁc drug biodistribution, thereby reducing the
side-effects and resistance. The majority of the i.v. injected con-
ventional nanoparticles (not surface-modiﬁed) are rapidly taken
by liver macrophages in addition to other reticuloendothelial
organs, but not by hepatocytes which are the major target for
anti-HBV drugs/genes. Thus, hepatocyte-speciﬁc drug/gene deliv-
ery has been achieved by:
(i) Using nanoparticles (also known as bionanocapsules)
designed with an HBV envelope (50 nm size) surface coated
with pre-S1 peptide that speciﬁcally recognizes the human hepa-
tocytes. Bionanocapsules are 50 nm hollow nanoparticles made
up of HBV envelope L (pre-S1 + pre-S2 + S) protein, consisting of
about 110 hepatitis B virus surface antigen molecules produced
from the recombinant yeast cells, and a lipid bilayer. The bio-
nanocapsules possessed membrane fusion potential, similar to
that of HBV, and thus delivered the drug payload to the cell cyto-
plasm. Furthermore, these bionanocapsules were successfully
conjugated with liposomes (the size of the bionanocapsule/lipo-
some complex is 150 nm) in order to deliver large materials, such
as proteins/peptides, as demonstrated using a murine model [15].
(ii) High density lipoprotein (HDL): HDL is implicated in the
return and deposition in the liver of cholesterol collected from
peripheral tissues. Liver homing of HDL is mediated by the asso-
ciated apolipoprotein A-1 (Apo A-1), a ligand binding to the scav-
enger receptor class-B type-I (SR-BI), expressed on the surface of
hepatocytes. Biomimicking HDL may, therefore, represent an
exciting strategy to deliver anti-HBV drug/gene to the hepato-
cytes. For instance, the i.v. injected acyclovir palmitate-recombi-
nant HDL complex lipid nanoparticles (diameter 33 nm) showed
4-fold greater hepatic accumulation than that of the free drug in
rats [16].
(iii) employing HBV-speciﬁc siRNA: HBV-speciﬁc siRNA





Fig. 2. Schematic representation of the hepatic homing of intravenously
injected therapeutic agent-loaded nanoparticle/liposome (not surface-mod-
iﬁed). Hepatic macrophages are the hosts for parasite colonies in case of liver
infections.
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injected into an HBV transgenic murine model, resulted in 3-fold
higher suppression of HBV replication markers (circulating viral
particle and intrahepatic HBV mRNA), and hence to an improved
efﬁcacy relative to controls [17]. In this construction, it is note-
worthy that the acidic pH-labile oxime linkage generated from
PEG coupling facilitated the release of siRNA from endosomes in-
side hepatic cells [17]. In another example, i.v. injected PEGylated
cationic liposomal siRNA resulted in considerable reduction in
HBV DNA compared to free siRNA; this was attributed to the
longer half-life of the transported siRNA in plasma and the liver
[18].
Targeting macrophages
Cryptococcosis, histoplasmosis, leishmaniasis, listeriosis, salmo-
nellosis etc. are examples of liver infections where the microor-
ganism resides and replicates in the host macrophages. In the
case of visceral leishmaniasis (i.e. kala-azar disease), the parasite
is localized in the macrophages of the liver and spleen, and is
resistant to lysosomal enzymes. Numerous studies have taken
advantage of the natural capture of i.v. injected nanoparticles
by Kupffer cells to deliver anti-infectious drugs selectively to
the parasite-colonized macrophages, thus increasing drug expo-
sure of infected cells (Fig. 2). Alving and co-workers ﬁrst showed
the use of liposomes for improving the efﬁcacy and safety of anti-
leishmanial drugs in experimental leishmaniasis models [19].
Intracellular co-localization of liposomes and leishmania para-
sites has been evidenced by the same authors. This pioneering
study has resulted in various marketed anti-leishmanial nan-
omedicines containing Amphotericin B, (AmB) such as liposomal
AmB (Ambisome), AmB colloidal dispersion (formulation in
sodium cholesteryl sulfate, Amphocil), and AmB lipid complex
(formulation in L-a-dimyristoylphosphatidylcholine and L-a-
dimyristoylphosphatidylglycerol, Abelcet). These nanomedi-
cines are also recommended for other intracellular infections
such as mycoses (i.e. Candida albicans) and cryptococcal infec-
tions. While these nanoformulations have considerably improved
the safety of AmB, Ambisome has shown to be the least nephro-
toxocity and hypokalaemia (reviewed in [20]). Liposomes (quer-
cetin, harmine, atovaquone, miltefosine, etc.) and polymeric
nanoparticles (primaquine, pentamidine) have also been used
to deliver other antiparasitic compounds than AmB. The antibac-
terial efﬁcacy of antibiotics loaded onto nanoparticles and lipo-
somes was also tested in experimental models of liver
intracellular infections. For instance, a single dose of 0.8 mg
ampicillin loaded onto biodegradable polyhexylcyanoacrylate
nanoparticles was able to cure experimental salmonellosis in
mice whereas with free ampicillin, a similar curative effect
required three doses of 32 mg each [21].Hepatic cancer
Hepatocellular carcinoma (HCC) is the most common primary
malignancy of the liver in adults and is the third most common
cause of cancer death worldwide, linked to the prevalence of
hepatitis B virus infection, alcohol consumption, and other
causes of hepatic cirrhosis. The treatment of HCC is complicated
due to multiple pathologies in several cases, despite the avail-
ability of different options, such as liver transplantation, surgical
resection, and locoregional therapies like radiofrequency abla-Journal of Hepatology 2011tion and transarterial chemoembolisation [22]. One of the major
reasons for chemotherapy failure of HCC is its chemoresistance
to various antitumor agents. Additionally, the distribution of
oral or i.v. injected chemotherapeutics to the tumor site is often
insufﬁcient. Thus, increasing the drug concentration in the
hepatic tissue where the HCC tumor is localized, prolonging
exposure of tumor tissue to the treatment, and thereby address-
ing the chemoresistance issue was believed to contribute to the
therapeutic improvement, simultaneously decreasing side-
effects by reducing the drug concentration in healthy tissues.
Some of the nanomedicines have achieved reasonable clinical
success to date.
(i) Polymeric nanoparticles: doxorubicin transdrug (DT) is a
doxorubicin loaded poly(isohexyl cyanoacrylate) nanoparticle
formulation that showed considerable antitumor activity against
multidrug-resistant protein-overexpressing hepatocellular carci-
noma in vivo model [23]. This nanomedicine is currently under
clinical trial for the treatment of liver tumors. In HCC patients,
single dose 40 mg/m2 intra-arterial hepatic injection was found
to be the MTD of DT, and was accompanied by major toxicities,
such as grade-4 neutropenia, severe hypotension, pseudo-allergic
reactions, and acute respiratory distress syndrome, while 35 mg/
m2 was considered to be the dose with acceptable safety [24]. In a
recent phase II trial that compared the efﬁcacy of DT (30 mg/m2
repeated doses) versus the current standard of care (transarterial
chemoembolisation with a cytotoxic drug), 88.9% survival rate
was observed after 18 months of DT treatment against onlyvol. 55 j 1461–1466 1463
Hyperthermia Blood vessel
Fig. 3. Mechanism of hyperthermia-induced liposomal drug release inside the tumor tissue and tumor cell death, following liposomal accumulation into tumor by
the EPR (i.e. ‘‘Enhanced Permeability and Retention’’) effect.
Clinical Application of Basic Science54.5% survival rate in patients treated with the current standard
of care [25], while similar toxic events as observed during phase I
study were the major side-effects.
Another nanoparticle that has been tested in clinic (phase II) is
Mitoxantrone-loaded polybutylcyanacrylate (PBCA) nanoparticle
i.v. formulation. This treatment showed a slight improvement
in efﬁcacy with a 2.2 month higher median survival time, a
10.5% objective response rate (ORR) versus no ORR in free
mitoxantrone-treated group, and also an improved safety, as
compared to free mitoxantrone [26]. It would be interesting to
see if this slight efﬁcacy improvement argues for further clinical
development of this formulation.
(ii) Thermosensitive liposome (Thermodox) (in conjunction
with hyperthermia): this drug delivery concept is based on the
injection of a liposomal formulation made of lysophospholipids
which decreased the phase transition temperature of the liposo-
mal membrane down to 39–40 C. After speciﬁc tumor extravasa-
tion of liposomes, the heating of the diseased tissue may trigger
drug release from the liposomes (Fig. 3). This approach has been
successfully applied to the anticancer compound doxorubicin and
has resulted in higher local drug concentrations and hence con-
siderably higher antitumor activity, in an in vivo xenografted
model, compared to non-thermosensitive liposomes [27]. Apart
from being cytotoxic, Thermodox caused the shutdown of tumor
blood ﬂow and thus acted as an antivascular agent too, creating
damage to the deeper tumor tissue. In a phase I study, Thermo-
dox (30 mg/m2) in conjunction with radiofrequency ablation
(RFA) showed improved safety with mild alopecia and neutrope-
nia, and absence of cardiotoxicity, renal toxicity, and hand–foot
syndrome which was previously observed in a considerable
patient population treated with poly(ethylene glycol)-liposomal
doxorubicin [28]. A phase III trial of Thermodox in conjunction
with RFA, in patients suffering from non-resectable hepatocellu-
lar carcinoma, (the HEAT study) (clinical trial identiﬁer:
NCT00617981) is ongoing.
In addition to the above, approaches such as magnetic ﬂuid
hyperthermia (heating the magnetic nanoparticles using an1464 Journal of Hepatology 2011externally-applied alternating magnetic ﬁeld) combined with
pharmacotherapy by employing drug-loaded polymer-coated
magnetite nanoparticles [29], and homing device-mediated
active targeting (by targeting asialoglycoprotein receptors over-
expressed on hepatic cells) using galactosylated polymeric nano-
particles [30] have been attempted for hepatic tumor treatment
in preclinical models, with reasonable success. In the former case,
carboplatin was non-covalently encapsulated into chitosan and
then coated onto the magnetic nanoparticles to provide a sus-
tained drug release. These intra-arterially injected nanoparticles
were guided to the transplanted liver tumor in mice, which was
then subjected to hyperthermia; a superior antitumor efﬁcacy
(tumor weight inhibition ratio of 93% and prolonged survival
time) was observed compared to the antitumor activity in the
absence of hyperthermia. In the latter case, low molecular weight
chitosan nanoparticles surface-modiﬁed with galactose residues
were non-covalently loaded with doxorubicin. These nanoparti-
cles were demonstrated to be taken up by hepatic cells through
the asialoglycoprotein receptor in vitro, whereas no proof-of-con-
cept has been done in vivo. Gene delivery has also been
attempted for the treatment of liver tumors. For instance, anti-
human bcl-2 siRNA complexed with cationic liposomes (com-
posed of 2-O-(2-diethylaminoethyl)-carbamoyl-1,3-O-dioleoyl-
glycerol and egg phosphatidylcholine) resulted in a signiﬁcant
reduction of liver tumor nodules after i.v. injection in a murine
model, as opposed to free siRNA [31].Liver imaging using superparamagnetic iron oxide
nanoparticles (SPION)
Although a variety of imaging approaches for HCC diagnosis are
in practice, such as dynamic computed tomography and
dynamic/non-enhanced/enhanced magnetic resonance imaging
(MRI), SPION-enhanced MRI has maintained an important role
in both pre-treatment and follow-up diagnosis/imaging of differ-
ent types of HCC. Following i.v. injection, SPIONs having a meanvol. 55 j 1461–1466
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particle diameter of 150 nm are rapidly sequestered by the Kupf-
fer cells of the liver; this process results in increased tumor:liver
contrast because the tumor does not contain Kupffer cells [32].
For instance, hypovascular HCC, which was not observed follow-
ing a dynamic Gd-contrast investigation, has been detected on
SPION images. Moreover, SPION facilitates differentiation
between benign hepatocellular lesions/dysplastic nodules and
HCC because SPIONs accumulate in the former but not in the lat-
ter. However, this methodology suffers from certain drawbacks,
such as the inability to assess lesion vascularity and limited
decrease in signal intensity of cirrhotic liver compared to that
of the normal liver [33]. Ferumoxide (dextran-coated SPION, End-
orem, Ferridex) and Ferucarbotran (carboxydextran-coated SPI-
ON, Resovist) are the two SPIONS clinically approved for liver
cancer imaging. Interestingly, UltraSPION has recently been
employed for the construction of a ‘‘nanotheragnostic’’ system
(i.e. combining anticancer and imaging properties), by embed-
ding into squalenoyl-drug conjugate nanoparticles [34].Conclusions
Nanotechnology has contributed toward the efﬁcient delivery of
therapeutic compounds for hepatic diseases and toward hepatic
imaging, as evidenced by the commercialized liposomal Ampho-
tericin B and the imaging agents Endorem and Resovist, as well
as by doxorubicin Transdrug, mitoxantrone-loaded PBCA nano-
particles, and Thermodox, which are currently in clinical devel-
opment. As a result, various nanomedicines are currently either
commercialized or under clinical testing for treatment or imag-
ing of hepatic diseases. It is the opinion of the authors of the
current review that forthcoming research efforts will have to
concentrate on the development of multifunctional nanomedi-
cine possessing both therapeutic and diagnostic capabilities,
by which the individual therapeutic dose could be titrated and
the therapy better monitored. Such nanomedicines are expected
to address the current clinical limitations in hepatic disease
therapy.Conﬂict of interest
The authors declared that do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
Acknowledgment
The authors thank Simon Harrisson for proof reading of the
manuscript.
References
[1] Li F, Wang J-y. Targeted delivery of drugs for liver ﬁbrosis. Expert Opin Drug
Deliv 2009;6:531–541.
[2] Alving CR. Delivery of liposome-encapsulated drugs to macrophages.
Pharmac Ther 1983;22:407–424.
[3] Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex
disease. Pharm Res 2006;23:1417–1450.
[4] Knittel T, Kobold D, Saile B, Grundmann A, Neubauer K, Piscaglia F, et al. Rat
liver myoﬁbroblasts and hepatic stellate cells: different cell populations of
the ﬁbroblast lineage with ﬁbrogenic potential. Gastroenterology
1999;117:1205–1221.Journal of Hepatology 2011[5] Beljaars L, Olinga P, Molema G, de Bleser P, Geerts A, Groothuis GMM,
et al. Characteristics of the hepatic stellate cell-selective carrier man-
nose 6-phosphate modiﬁed albumin (M6P28-HSA). Liver 2001;21:
320–328.
[6] Adrian JE, Kamps JA, Poelstra K, Scherphof GL, Meijer DK, Kaneda Y. Delivery
of viral vectors to hepatic stellate cells in ﬁbrotic livers using HVJ envelopes
fused with targeted liposomes. J Drug Target 2007;15:75–82.
[7] Beljaars L, Molema G, Schuppan D, Geerts A, De Bleser PJ, Weert B, et al.
Successful targeting to rat hepatic stellate cells using albumin modiﬁed with
cyclic peptides that recognize the collagen type VI receptor. J Biol Chem
2000;275:12743–12751.
[8] Du S-L, Pan H, Lu W-Y, Wang J, Wu J, Wang J-Y. Cyclic Arg-Gly-Asp peptide-
labeled liposomes for targeting drug therapy of hepatic ﬁbrosis in rats. J
Pharmacol Exp Ther 2007;322:560–568.
[9] Sato Y, Murase1 K, Kato J, Kobune M, Sato T, Kawano Y, et al. Resolution of
liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a
collagen-speciﬁc chaperone. Nat Biotechnol 2008;26:431–442.
[10] Mandal AK, Das S, Chakrabarti BasuMK, RN DasN. Hepatoprotective activity
of liposomal ﬂavonoid against arsenite-induced liver ﬁbrosis. J Pharmacol
Exp Ther 2007;320:994–1001.
[11] Melgert BN, Olinga P, Jack VK, Molema G, Meijer DKF, Poelstra K.
Dexamethasone coupled to albumin is selectively taken up by rat nonpa-
renchymal liver cells and attenuates LPS-induced activation of hepatic cells.
J Hepatol 2000;32:603–611.
[12] Wang H, Wei W, Zhang S-Y, Shen Y-X, Yue L, Wang N-P, et al. Melatonin–
selenium nanoparticles inhibit oxidative stress and protect against hepatic
injury induced by Bacillus Calmette–Guerin/lipopolysaccharide in mice. J
Pineal Res 2005;39:156–163.
[13] Wu J, Liu L, Yen RD, Catana A, Nantz MH, Zern MA. Liposome-mediated
extracellular superoxide dismutase gene delivery protects against acute
liver injury in mice. Hepatology 2004;40:195–204.
[14] Wang G-F, Shi L-P, Zuo J-P. Anti-hepatitis B virus drugs in clinical and
preclinical development. Virol Sin 2008;23:137–145.
[15] Jung J, Matsuzaki T, Tatematsu K, Okajima T, Tanizawa K, Kuroda S. Bio-
nanocapsule conjugated with liposomes for in vivo pinpoint delivery of
various materials. J Control Rel 2008;126:255–264.
[16] Feng M, Cai Q, Huang H, Zhou P. Liver targeting and anti-HBV activity of
reconstituted HDL-acyclovir palmitate complex. Eur J Pharm Biopharm
2008;68:688–693.
[17] Carmona S, Jorgensen MR, Kolli S, Crowther C, Salazar FH, Marion
PL, et al. Controlling HBV replication in vivo by intravenous
administration of triggered PEGylated siRNA-nanoparticles. Mol Pharm
2009;6:706–717.
[18] Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, et al.
Potent and persistent in vivo anti-HBV activity of chemically modiﬁed
siRNAs. Nat Biotechnol 2005;23:1002–1007.
[19] Alving CR, Steck EA, Chapman Jr WL, Waits VB, Hendrick LD, Swartz Jr GM,
et al. Therapy of leishmaniasis: superior efﬁcacies of liposome-encapsulated
drugs. Proc Nat Acad Sci USA 1978;75:2959–2963.
[20] Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal Amphotericin B a
review of its use as empirical therapy in febrile neutropenia and in the
treatment of invasive fungal infections. Drugs 2009;69:361–392.
[21] Fattal E, Youssef M, Couvreur P, Andremont A. Treatment of experimental
salmonellosis in mice with ampicillin-bound nanoparticles. Antimicrob
Agents Chemother 1989;33:1540–1543.
[22] Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, et al.
Hepatocellular Carcinoma: consensus recommendations of the national
cancer institute clinical trials planning meeting. J Clin Oncol
2010;28:3994–4005.
[23] Barraud L, Merle P, Soma E, Lefrancois L, Guerret S, Chevallier M, et al.
Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparti-
cles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol
2005;42:736–743.
[24] Merle P, Si Ahmed S, Habersetzer F, Abergel A, Taieb J, Bonyhay L, et al. Phase
1 study of intra-arterial hepatic (IAH) delivery of doxorubicin-transdrug (DT)
for patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol
2006 [ASCO annual meeting proceedings Part I. 2006; 24, No. 18S: (June 20
Supplement): 14094].
[25] Doxorubicin Transdrug: signiﬁcant increased survival rate in patients with
advanced hepatocellular carcinoma treated in a phase II clinical trial.
Bioalliance web document 2009; 8 Dec.
[26] Zhou Q, Sun X, Zeng L, Liu J, Zhang Z. A randomized multicenter phase II
clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108
patients with unresected hepatocellular carcinoma. Nanomed Nanotech Biol
Med 2009;5:419–423.vol. 55 j 1461–1466 1465
Clinical Application of Basic Science
[27] Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D,
et al. Efﬁcacy of liposomes and hyperthermia in a human tumor xenograft
model: importance of triggered drug release. Cancer Res 2000;60:
6950–6957.
[28] Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated
liposomal doxorubicin-related palmar–plantar erythrodysesthesia (‘hand–
foot’ syndrome). Ann Oncol 2007;18:1159–1164.
[29] Li F-R, Yan W-H, Guo Y-H, Qi H, Zhou H-X. Preparation of carboplatin-
Fe@C-loaded chitosan nanoparticles and study on hyperthermia combined
with pharmacotherapy for liver cancer. Int J Hyperthermia
2009;25:383–391.
[30] Jain NK, Jain SK. Development and in vitro characterization of galactosylated
low molecular weight chitosan nanoparticles bearing doxorubicin. AAPS
PharmSciTech 2010;11:686–697.1466 Journal of Hepatology 2011[31] Yano J, Hirabayashi K, Nakagawa S, Yamaguchi T, Nogawa M, Kashimori I,
et al. Antitumor activity of small interfering RNA/cationic liposome complex
in mouse models of cancer. Clin Cancer Res 2004;10:7721–7726.
[32] Digumarthy SR, Sahani DV, Saini S. MRI in detection of hepatocellular
carcinoma (HCC). Cancer Imaging 2005;5:20–24.
[33] Tanimoto A, Kuribayashi S. Application of superparamagnetic iron
oxide to imaging of hepatocellular carcinoma. Eur J Radiol 2006;58:
200–216.
[34] Arias JL, Reddy LH, Othman M, Gillet B, Desmaele D, Zouhiri F, et al. Squalene
based nanocomposites: a new platform for the design of multifunctional
pharmaceutical theragnostics. ACS Nano 2011;5:1513–1521.vol. 55 j 1461–1466
